An Open Label, Multi-Center Study to Determine the Safety and Pharmacokinetics of Intravenous and Oral APX001 in Patients Undergoing Chemotherapy for Acute Myeloid Leukemia With Neutropenia
Phase of Trial: Phase I
Latest Information Update: 21 Nov 2018
Price : $35 *
At a glance
- Drugs Fosmanogepix (Primary) ; Fosmanogepix (Primary)
- Indications Acute myeloid leukaemia
- Focus Adverse reactions
- Sponsors Amplyx Pharmaceuticals
- 08 Nov 2018 Status changed from active, no longer recruiting to completed.
- 21 Sep 2018 Planned End Date changed from 1 Aug 2018 to 1 Oct 2018.
- 21 Sep 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.